Andrzej Potemkowski

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Raju Kapoor, Pei‐Ran Ho, Nolan Campbell et al. · The Lancet Neurology · 2018 · 337 citations · Full text

Life Sciences, Neurology, Pharmacotherapy +14

Safety and efficacy of opicinumab in patients with relapsing multiple sclerosis (SYNERGY): a randomised, placebo-controlled, phase 2 trial

Diego Cadavid, Michelle Mellion, Raymond Hupperts et al. · The Lancet Neurology · 2019 · 185 citations

Life Sciences, Immunology, Neurology +11

Safety and tolerability of inebilizumab (MEDI-551), an anti-CD19 monoclonal antibody, in patients with relapsing forms of multiple sclerosis: Results from a phase 1 randomised, placebo-controlled, escalating intravenous and subcutaneous dose study

Mark Agius, Gabriela Kłodowska-Duda, Maciej Maciejowski et al. · Multiple Sclerosis Journal · 2017 · 142 citations · Full text

Life Sciences, Immunology, Neurology +17

Pattern electroretinogram (PERG) and pattern visual evoked potential (PVEP) in the early stages of Alzheimer’s disease

Kamila Krasodomska, Wojciech Lubiński, Andrzej Potemkowski et al. · Documenta Ophthalmologica · 2010 · 134 citations · Full text

Medicine, Neurology, Ophthalmology +16

Characterizing absolute lymphocyte count profiles in dimethyl fumarate–treated patients with MS

Robert J. Fox, Andrew Chan, Ralf Gold et al. · Neurology Clinical Practice · 2016 · 104 citations · Full text

Life Sciences, Immunology, Pharmacology +14